PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mr. DARSHAN LAL				
AGE/ GENDER	: 76 YRS/MALE	]	PATIENT ID	: 1653837	
COLLECTED BY	:	]	REG. NO./LAB NO.	: 122410	290018
<b>REFERRED BY</b>	:	]	REGISTRATION DATE	: 29/0ct/2	2024 02:03 PM
BARCODE NO.	: 12505396		COLLECTION DATE	: 29/Oct/2	2024 02:18PM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INS	TITUTE I	REPORTING DATE	: 29/0ct/2	2024 04:09PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA				
Test Name		Value	Unit	I	Biological Reference interval
			TOLOGY		
	GLYO	COSYLATED HA	EMOGLOBIN (HBA1	<b>C)</b>	
GLYCOSYLATED HAE WHOLE BLOOD	MOGLOBIN (HbA1c):	5.5	%	4	.0 - 6.4
ESTIMATED AVERAGE PLASMA GLUCOSE by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)		111.15	mg/dL	6	0.00 - 140.00
INTERPRETATION:					
	AS PER AMERICAN DIAB				
	FERENCE GROUP	GLYCOSYLATED HEMOGLOGIB (HBAIC) in %		C) in %	
	etic Adults >= 18 years	<5.7			
	Risk (Prediabetes)	5.7 - 6.4			
Diag	gnosing Diabetes	>= 6.5			
Therapeutic goals for glycemic control		Goals of Ther	Age > 19 Years	7.0	
		Actions Sugges		8.0	
Inerapeutic				0.0	
Therapeutic			Age < 19 Years		

## COMMENTS:

1. Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients.

2.Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropriate. 4. High

HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications

5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)


440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



## PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana) A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

Test Name	Value	Unit	Biological Reference interval
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY	- HARYANA	
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	<b>REPORTING DATE</b>	: 29/Oct/2024 04:09PM
BARCODE NO.	: 12505396	COLLECTION DATE	: 29/Oct/2024 02:18PM
<b>REFERRED BY</b>	:	<b>REGISTRATION DATE</b>	: 29/Oct/2024 02:03 PM
COLLECTED BY	:	<b>REG. NO./LAB NO.</b>	: 122410290018
AGE/ GENDER	: 76 YRS/MALE	PATIENT ID	: 1653837
NAME	: Mr. DARSHAN LAL		







**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)** 



**PKR JAIN HEALTHCARE INSTITUTE** NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mr. DARSHAN LAL			
AGE/ GENDER	: 76 YRS/MALE		PATIENT ID	: 1653837
COLLECTED BY	:		REG. NO./LAB NO.	: 122410290018
REFERRED BY	:		<b>REGISTRATION DATE</b>	: 29/Oct/2024 02:03 PM
BARCODE NO.	: 12505396		<b>COLLECTION DATE</b>	: 29/Oct/2024 02:18PM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INS	STITUTE	<b>REPORTING DATE</b>	: 29/Oct/2024 04:20PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AI	MBALA CITY - H	ARYANA	
Test Name		Value	Unit	<b>Biological Reference interval</b>
	CLINIC	CAL CHEME	STRY/BIOCHEMIST	RY
		LIPID PR	OFILE : BASIC	
CHOLESTEROL TO by CHOLESTEROL O		125	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0
TRIGLYCERIDES: S by GLYCEROL PHOSE	ERUM PHATE OXIDASE (ENZYMATIC)	131.26	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0
HDL CHOLESTERO by SELECTIVE INHIBIT	L (DIRECT): SERUM Ton	53.54	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTERO by CALCULATED, SPE		45.21	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0
NON HDL CHOLES' by calculated, spe		71.46	mg/dL	VERY HIGH: > OR = 190.0 OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTER		26.25	mg/dL	0.00 - 45.00
by CALCULATED, SPE TOTAL LIPIDS: SEE by CALCULATED, SPE	RUM	381.26	mg/dL	350.00 - 700.00
CHOLESTEROL/HI		2.33	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0

**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)** 



Page 3 of 4

PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mr. DARSHAN LAL		
AGE/ GENDER	: 76 YRS/MALE	PATIENT ID	: 1653837
<b>COLLECTED BY</b>	:	REG. NO./LAB NO.	: 122410290018
<b>REFERRED BY</b>	:	<b>REGISTRATION DATE</b>	: 29/Oct/2024 02:03 PM
BARCODE NO.	: 12505396	<b>COLLECTION DATE</b>	: 29/Oct/2024 02:18PM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	<b>REPORTING DATE</b>	: 29/Oct/2024 04:20PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - )	HARYANA	
Test Name	Value	Unit	<b>Biological Reference interval</b>
-			MODERATE RISK: 7.10 - 11.0

LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	0.84	RATIO	HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0
		DATIO	HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	2.45 <sup>L</sup>	RATIO	3.00 - 5.00

## **INTERPRETATION:**

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDI

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

\*\*\* End Of Report \*\*\*





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)** 

